LONDON (ShareCast) - (ShareCast News) - AIM-listed digital technologies company IXICO has signed an extension and expansion to its largest existing contract for a Phase II/III clinical trial in Alzheimer's disease.
The total contract value has risen from $6.8m to $7.7m, of which $1.0m has been recognised to date and the term has been extended by eight months to May 2024.

In the study, IXICO measures and monitors changes in disease pathology of participants in the trial. It said the expansion reflects the addition of further image data standardisation and collection services, which will be provided over the duration of the study.

Chief executive officer Giulio Cerroni said: "We are delighted to announce an extension to this significant existing agreement which reflects the opportunities we continue to develop to enhance our privileged position as trusted partners, to provide additional technology enabled services to our pharmaceutical customers."

At 1025 BST, the shares were up 0.2% to 33.05p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE